NEW YORK (GenomeWeb News) – Illumina and Genpathway have partnered to offer scientists a solution for studying transcription factor binding and gene regulation in drug development research, Illumina said today.
 
Under the partnership, Genpathway will prepare samples using its FactorPath ChIP assays and will conduct data analysis using its software. The sequencing will be handled by Illumina’s Sequencing Services, which will employ the firm’s high-throughput Genome Analyzer, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.